Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other Non-Current Assets: 2009-2024

Historic Other Non-Current Assets for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to $2.8 million.

  • Cumberland Pharmaceuticals' Other Non-Current Assets rose 5.55% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 5.55%. This contributed to the annual value of $2.8 million for FY2024, which is 3.38% up from last year.
  • Cumberland Pharmaceuticals' Other Non-Current Assets amounted to $2.8 million in FY2024, which was up 3.38% from $2.7 million recorded in FY2023.
  • Over the past 5 years, Cumberland Pharmaceuticals' Other Non-Current Assets peaked at $3.4 million during FY2021, and registered a low of $2.5 million during FY2022.
  • In the last 3 years, Cumberland Pharmaceuticals' Other Non-Current Assets had a median value of $2.7 million in 2023 and averaged $2.7 million.
  • In the last 5 years, Cumberland Pharmaceuticals' Other Non-Current Assets declined by 26.29% in 2022 and then increased by 6.83% in 2023.
  • Over the past 5 years, Cumberland Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $3.2 million in 2020, then grew by 5.74% to $3.4 million in 2021, then dropped by 26.29% to $2.5 million in 2022, then climbed by 6.83% to $2.7 million in 2023, then increased by 3.38% to $2.8 million in 2024.